People have the right to be involved in discussions and make informed decisions about their care, as described in NICE's information on making decisions about your care.
Making decisions using NICE guidelines explains how we use words to show the strength (or certainty) of our recommendations, and has information about prescribing medicines (including off-label use), professional guidelines, standards and laws (including on consent and mental capacity), and safeguarding.
22.214.171.124 To aid management of atopic eczema in children, healthcare professionals should take detailed clinical and drug histories that include questions about:
time of onset, pattern and severity of the atopic eczema
response to previous and current treatments
possible trigger factors (irritant and allergic)
the impact of the atopic eczema on children and their parents or carers
dietary history including any dietary manipulation
growth and development
personal and family history of atopic diseases.
126.96.36.199 Atopic eczema should be diagnosed when a child has an itchy skin condition plus 3 or more of the following:
visible flexural dermatitis involving the skin creases, such as the bends of the elbows or behind the knees (or visible dermatitis on the cheeks and/or extensor areas in children aged 18 months or under)
personal history of flexural dermatitis (or dermatitis on the cheeks and/or extensor areas in children aged 18 months or under)
personal history of dry skin in the last 12 months
personal history of asthma or allergic rhinitis (or history of atopic disease in a first-degree relative of children aged under 4 years)
onset of signs and symptoms under the age of 2 years (this criterion should not be used in children aged under 4 years).
Healthcare professionals should be aware that in Asian, black Caribbean and black African children, atopic eczema can affect the extensor surfaces rather than the flexures, and discoid (circular) or follicular (around hair follicles) patterns may be more common.
188.8.131.52 Healthcare professionals should inform children with atopic eczema and their parents or carers that the condition often improves with time, but that not all children will grow out of atopic eczema and it may get worse in teenage or adult life.
184.108.40.206 Healthcare professionals should inform children with atopic eczema and their parents or carers that children with atopic eczema can often develop asthma and/or allergic rhinitis and that sometimes food allergy is associated with atopic eczema, particularly in very young children.
irritants, for example soaps and detergents (including shampoos, bubble baths, shower gels and washing-up liquids)
220.127.116.11 Healthcare professionals should consider a diagnosis of food allergy in children with atopic eczema who have reacted previously to a food with immediate symptoms, or in infants and young children with moderate or severe atopic eczema that has not been controlled by optimum management, particularly if associated with gut dysmotility (colic, vomiting, altered bowel habit) or failure to thrive.
18.104.22.168 Healthcare professionals should consider a diagnosis of inhalant allergy in children with seasonal flares of atopic eczema, children with atopic eczema associated with asthma or allergic rhinitis, and children aged 3 years or over with atopic eczema on the face, particularly around the eyes.
22.214.171.124 Healthcare professionals should consider a diagnosis of allergic contact dermatitis in children with an exacerbation of previously controlled atopic eczema or with reactions to topical treatments.
126.96.36.199 Healthcare professionals should reassure children with mild atopic eczema and their parents or carers that most children with mild atopic eczema do not need to have tests for allergies.
188.8.131.52 Healthcare professionals should advise children with atopic eczema and their parents or carers not to undergo high street or internet allergy tests because there is no evidence of their value in the management of atopic eczema.
184.108.40.206 Healthcare professionals should offer a 6- to 8-week trial of an extensively hydrolysed protein formula or amino acid formula in place of cow's milk formula for bottle-fed infants aged under 6 months with moderate or severe atopic eczema that has not been controlled by optimal treatment with emollients and mild topical corticosteroids.
220.127.116.11 Healthcare professionals should refer children with atopic eczema who follow a cow's milk-free diet for longer than 8 weeks for specialist dietary advice.
18.104.22.168 Diets based on unmodified proteins of other species' milk (for example, goat's milk, sheep's milk) or partially hydrolysed formulas should not be used in children with atopic eczema for the management of suspected cow's milk allergy. Diets including soya protein can be offered to children aged 6 months or over with specialist dietary advice.
22.214.171.124 Healthcare professionals should inform women who are breastfeeding children with atopic eczema that it is not known whether altering the mother's diet is effective in reducing the severity of the condition. A trial of an allergen-specific exclusion diet should be considered under dietary supervision if food allergy is strongly suspected.
126.96.36.199 Healthcare professionals should inform children with atopic eczema and their parents or carers that it is unclear what role factors such as stress, humidity or extremes of temperature have in causing flares of atopic eczema. These factors should be avoided where possible.
188.8.131.52 Healthcare professionals should use a stepped approach for managing atopic eczema in children. This means tailoring the treatment step to the severity of the atopic eczema. Emollients should form the basis of atopic eczema management and should always be used, even when the atopic eczema is clear. Management can then be stepped up or down, according to the severity of symptoms, with the addition of the other treatments listed in table 2.
Mild atopic eczema
Moderate atopic eczema
Severe atopic eczema
184.108.40.206 Healthcare professionals should offer children with atopic eczema and their parents or carers information on how to recognise flares of atopic eczema (increased dryness, itching, redness, swelling and general irritability). They should give clear instructions on how to manage flares according to the stepped-care plan, and prescribe treatments that allow children and their parents or carers to follow this plan.
220.127.116.11 Treatment for flares of atopic eczema in children should be started as soon as signs and symptoms appear and continued for approximately 48 hours after symptoms subside.
Emollient creams are vital in helping to manage dry skin conditions. But there are Medicines and Healthcare products Regulatory Agency (MHRA) warnings about fire hazards associated with build-up of emollient residue on clothing and bedding.
18.104.22.168 Healthcare professionals should offer children with atopic eczema a choice of unperfumed emollients to use every day for moisturising, washing and bathing. This should be suited to the child's needs and preferences, and may include a combination of products or one product for all purposes. Leave-on emollients should be prescribed in large quantities (250 g to 500 g weekly) and easily available to use at nursery, pre-school or school.
22.214.171.124 Healthcare professionals should inform children with atopic eczema and their parents or carers that they should use emollients in larger amounts and more often than other treatments. Emollients should be used on the whole body both when the atopic eczema is clear and while using all other treatments.
126.96.36.199 Healthcare professionals should inform children with atopic eczema and their parents or carers that they should use emollients and/or emollient wash products instead of soaps and detergent-based wash products.
188.8.131.52 Healthcare professionals should advise parents or carers of children aged under 12 months with atopic eczema to use emollients and/or emollient wash products instead of shampoos for the child. If shampoo is used for older children with atopic eczema it should be unperfumed and ideally labelled as being suitable for eczema; washing the hair in bath water should be avoided.
184.108.40.206 Healthcare professionals should show children with atopic eczema and their parents or carers how to apply emollients, including how to smooth emollients onto the skin rather than rubbing them in.
220.127.116.11 Healthcare professionals should offer an alternative emollient if a particular emollient causes irritation or is not acceptable to a child with atopic eczema.
18.104.22.168 Healthcare professionals should review repeat prescriptions of individual products and combinations of products with children with atopic eczema and their parents or carers at least once a year to ensure that therapy remains optimal.
22.214.171.124 Where emollients (excluding bath emollients) and other topical products are used at the same time of day to treat atopic eczema in children, the different products should ideally be applied one at a time with several minutes between applications where practical. The preferences of the child and parents or carers should determine which product should be applied first.
Recommendations 126.96.36.199 and 188.8.131.52 are from NICE's technology appraisal guidance on frequency of application of topical corticosteroids for atopic eczema.
184.108.40.206 Healthcare professionals should discuss the benefits and harms of treatment with topical corticosteroids with children with atopic eczema and their parents or carers, emphasising that the benefits outweigh possible harms when they are applied correctly.
220.127.116.11 The potency of topical corticosteroids should be tailored to the severity of the child's atopic eczema, which may vary according to body site. They should be used as follows:
use mild potency for mild atopic eczema
use moderate potency for moderate atopic eczema
use potent for severe atopic eczema
use mild potency for the face and neck, except for short-term (3 to 5 days) use of moderate potency for severe flares
use moderate or potent preparations for short periods only (7 to 14 days) for flares in vulnerable sites such as axillae and groin
do not use very potent preparations in children without specialist dermatological advice.
18.104.22.168 It is recommended that topical corticosteroids for atopic eczema should be prescribed for application only once or twice daily.
22.214.171.124 It is recommended that where more than 1 alternative topical corticosteroid is considered clinically appropriate within a potency class, the drug with the lowest acquisition cost should be prescribed, taking into account pack size and frequency of application.
126.96.36.199 Healthcare professionals should inform children with atopic eczema and their parents or carers that they should only apply topical corticosteroids to areas of active atopic eczema (or eczema that has been active within the past 48 hours – see recommendation 188.8.131.52), which may include areas of broken skin.
184.108.40.206 Healthcare professionals should exclude secondary bacterial or viral infection if a mild or moderately potent topical corticosteroid has not controlled the atopic eczema within 7 to 14 days. In children aged 12 months or over, potent topical corticosteroids should then be used for as short a time as possible and in any case for no longer than 14 days. They should not be used on the face or neck. If this treatment does not control the atopic eczema, the diagnosis should be reviewed and the child referred for specialist dermatological advice.
220.127.116.11 Potent topical corticosteroids should not be used in children aged under 12 months without specialist dermatological supervision.
18.104.22.168 Healthcare professionals who dispense topical corticosteroids should apply labels stating the potency class of the preparations to the container (for example, the tube), not the outer packaging.
22.214.171.124 Healthcare professionals should consider treating problem areas of atopic eczema with topical corticosteroids for 2 consecutive days per week to prevent flares, instead of treating flares as they arise, in children with frequent flares (2 or 3 per month), once the eczema has been controlled. This strategy should be reviewed within 3 months to 6 months to assess effectiveness.
126.96.36.199 A different topical corticosteroid of the same potency should be considered as an alternative to stepping up treatment if tachyphylaxis to a topical corticosteroid is suspected in children with atopic eczema.
Recommendations 188.8.131.52 to 184.108.40.206 are from NICE's technology appraisal guidance on tacrolimus and pimecrolimus for atopic eczema.
220.127.116.11 Topical tacrolimus and pimecrolimus are not recommended for the treatment of mild atopic eczema or as first-line treatments for atopic eczema of any severity.
18.104.22.168 Topical tacrolimus is recommended, within its licensed indications, as an option for the second-line treatment of moderate to severe atopic eczema in adults and children aged 2 years and older that has not been controlled by topical corticosteroids (see recommendation 22.214.171.124), where there is a serious risk of important adverse effects from further topical corticosteroid use, particularly irreversible skin atrophy.
126.96.36.199 Pimecrolimus is recommended, within its licensed indications, as an option for the second-line treatment of moderate atopic eczema on the face and neck in children aged 2 years to 16 years that has not been controlled by topical corticosteroids (see recommendation 188.8.131.52), where there is a serious risk of important adverse effects from further topical corticosteroid use, particularly irreversible skin atrophy.
184.108.40.206 For the purposes of this guidance, atopic eczema that has not been controlled by topical corticosteroids refers to disease that has not shown a satisfactory clinical response to adequate use of the maximum strength and potency that is appropriate for the patient's age and the area being treated.
220.127.116.11 It is recommended that treatment with tacrolimus or pimecrolimus be initiated only by physicians (including general practitioners) with a special interest and experience in dermatology, and only after careful discussion with the patient about the potential risks and benefits of all appropriate second-line treatment options.
18.104.22.168 Healthcare professionals should explain to children with atopic eczema and their parents or carers that they should only apply topical calcineurin inhibitors to areas of active atopic eczema, which may include areas of broken skin.
22.214.171.124 Topical calcineurin inhibitors should not be used under occlusion (bandages and dressings) for treating atopic eczema in children without specialist dermatological advice.
126.96.36.199 For facial atopic eczema in children that requires long-term or frequent use of mild topical corticosteroids, consider stepping up treatment to topical calcineurin inhibitors.
188.8.131.52 Occlusive medicated dressings and dry bandages should not be used to treat infected atopic eczema in children.
184.108.40.206 Localised medicated dressings or dry bandages can be used with emollients as a treatment for areas of chronic lichenified (localised skin thickening) atopic eczema in children.
220.127.116.11 Localised medicated dressings or dry bandages with emollients and topical corticosteroids can be used for short-term treatment of flares (7 to 14 days) or areas of chronic lichenified atopic eczema in children.
18.104.22.168 Whole-body (limbs and trunk) occlusive dressings (including wet wrap therapy) and whole-body dry bandages (including tubular bandages and garments) should not be used as first-line treatment for atopic eczema in children and should only be initiated by a healthcare professional trained in their use.
22.214.171.124 Whole-body (limbs and trunk) occlusive dressings (including wet wrap therapy) with topical corticosteroids should only be used to treat atopic eczema in children for 7 to 14 days (or for longer with specialist dermatological advice), but can be continued with emollients alone until the atopic eczema is controlled.
126.96.36.199 Oral antihistamines should not be used routinely in the management of atopic eczema in children.
188.8.131.52 Healthcare professionals should offer a 1-month trial of a non-sedating antihistamine to children with severe atopic eczema or children with mild or moderate atopic eczema where there is severe itching or urticaria. Treatment can be continued, if successful, while symptoms persist, and should be reviewed every 3 months.
184.108.40.206 Healthcare professionals should offer a 7- to 14‑day trial of an age-appropriate sedating antihistamine to children aged 6 months or over during an acute flare of atopic eczema if sleep disturbance has a significant impact on the child or parents or carers. This treatment can be repeated during subsequent flares if successful.
For additional recommendations, see managing secondary bacterial infections of eczema in the NICE guideline on treating secondary bacterial infection of eczema and other common skin conditions: antimicrobial prescribing, which has updated recommendations in this section.
220.127.116.11 Children with atopic eczema and their parents or carers should be offered information on how to recognise the symptoms and signs of bacterial infection with staphylococcus and/or streptococcus (weeping, pustules, crusts, atopic eczema failing to respond to therapy, rapidly worsening atopic eczema, fever and malaise). Healthcare professionals should provide clear information on how to access appropriate treatment when a child's atopic eczema becomes infected.
18.104.22.168 Children with atopic eczema and their parents or carers should be informed that they should obtain new supplies of topical atopic eczema medications after treatment for infected atopic eczema because products in open containers can become contaminated with microorganisms and act as a source of infection.
22.214.171.124 Healthcare professionals should consider infection with herpes simplex (cold sore) virus if a child's infected atopic eczema fails to respond to treatment with antibiotics and an appropriate topical corticosteroid.
126.96.36.199 If a child with atopic eczema has a lesion on the skin suspected to be herpes simplex virus, treatment with oral aciclovir should be started even if the infection is localised.
188.8.131.52 If eczema herpeticum (widespread herpes simplex virus) is suspected in a child with atopic eczema, treatment with systemic aciclovir should be started immediately and the child should be referred for same-day specialist dermatological advice. If secondary bacterial infection is also suspected, treatment with appropriate systemic antibiotics should also be started.
184.108.40.206 If eczema herpeticum involves the skin around the eyes, the child should be treated with systemic aciclovir and should be referred for same-day ophthalmological and dermatological advice.
220.127.116.11 Children with atopic eczema and their parents or carers should be offered information on how to recognise eczema herpeticum. Signs of eczema herpeticum are:
areas of rapidly worsening, painful eczema
clustered blisters consistent with early-stage cold sores
punched-out erosions (circular, depressed, ulcerated lesions) usually 1 mm to 3 mm that are uniform in appearance (these may coalesce to form larger areas of erosion with crusting)
possible fever, lethargy or distress.
18.104.22.168 Healthcare professionals should consider phototherapy or systemic treatments for the treatment of severe atopic eczema in children when other management options have failed or are inappropriate and where there is a significant negative impact on quality of life. Treatment should be undertaken only under specialist dermatological supervision by staff who are experienced in dealing with children.
22.214.171.124 Phototherapy or systemic treatments should only be initiated in children with atopic eczema after assessment and documentation of severity of atopic eczema and quality of life (see recommendation 126.96.36.199).
188.8.131.52 Children with atopic eczema and their parents or carers should be informed that the effectiveness and safety of complementary therapies such as homeopathy, herbal medicine, massage and food supplements for the management of atopic eczema have not yet been adequately assessed in clinical studies.
184.108.40.206 Children with atopic eczema and their parents or carers should be informed that:
they should be cautious with the use of herbal medicines in children and be wary of any herbal product that is not labelled in English or does not come with information about safe usage (see the MHRA's using herbal medicines: advice to consumers)
topical corticosteroids are deliberately added to some herbal products intended for use in children with atopic eczema
liver toxicity has been associated with the use of some Chinese herbal medicines intended to treat atopic eczema.
220.127.116.11 Children with atopic eczema and their parents or carers should be asked to inform their healthcare professionals if they are using or intend to use complementary therapies.
18.104.22.168 Children with atopic eczema and their parents or carers should be informed that if they plan to use complementary therapies, they should keep using emollients as well.
22.214.171.124 Children with atopic eczema and their parents or carers should be advised that regular massage with emollients may improve the atopic eczema.
126.96.36.199 Healthcare professionals should spend time educating children with atopic eczema and their parents or carers about atopic eczema and its treatment. They should provide information in verbal and written forms, with practical demonstrations, and should cover:
how much of the treatments to use
how often to apply treatments
when and how to step treatment up or down
how to treat infected atopic eczema.
This should be reinforced at every consultation, addressing factors that affect adherence.
188.8.131.52 When discussing treatment options with children with atopic eczema and their parents and carers, healthcare professionals should tailor the information they provide to suit the child's cultural practices relating to skin care (including oiling the skin) and the way they bathe.
184.108.40.206 Healthcare professionals should inform children with atopic eczema and their parents or carers that atopic eczema may temporarily cause the skin to become lighter or darker.
220.127.116.11 Immediate (same-day) referral for specialist dermatological advice is recommended if eczema herpeticum is suspected (see recommendations 18.104.22.168 and 22.214.171.124 for details).
126.96.36.199 Urgent (within 2 weeks) referral for specialist dermatological advice is recommended for children with atopic eczema if:
the atopic eczema is severe and has not responded to optimum topical therapy after 1 week
treatment of bacterially infected atopic eczema has failed.
188.8.131.52 Referral for specialist dermatological advice is recommended for children with atopic eczema if:
the diagnosis is, or has become, uncertain
management has not controlled the atopic eczema satisfactorily based on a subjective assessment by the child, parent or carer (for example, the child is having 1 to 2 weeks of flares per month or is reacting adversely to many emollients)
atopic eczema on the face has not responded to appropriate treatment
the child or parent/carer may benefit from specialist advice on treatment application (for example, bandaging techniques)
contact allergic dermatitis is suspected (for example, persistent atopic eczema or facial, eyelid or hand atopic eczema)
the atopic eczema is giving rise to significant social or psychological problems for the child or parent or carer (for example, sleep disturbance, poor school attendance)
atopic eczema is associated with severe and recurrent infections, especially deep abscesses or pneumonia.
184.108.40.206 Children with atopic eczema that has responded to optimum management but for whom the impact of the atopic eczema on quality of life and psychosocial wellbeing has not improved should be referred for psychological advice.
220.127.116.11 Children with moderate or severe atopic eczema and suspected food allergy should be referred for specialist investigation and management of the atopic eczema and allergy.
18.104.22.168 Children with atopic eczema who fail to grow at the expected growth trajectory, as reflected by UK growth charts, should be referred for specialist advice relating to growth.